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Purified protein vaccines often require adjuvants for efficient stimulation of immune responses. There is no licensed mucosal
adjuvant on the market to adequately boost the immune response to purified antigens for intranasal applications in humans.
Bacterial outer membrane vesicles (OMV) are attractive candidates potentially combining antigenic and adjuvant properties in
one substance. To more precisely characterize the potential of Escherichia coli OMV for intranasal vaccination with heterologous
antigens, immune responses for AnAPN1 and Pfs48/45 as well as ovalbumin as a reference antigen were assessed in mice. The
intranasal adjuvant cholera toxin (CT) and parenteral adjuvantMF59C.1 were used in comparison. Vaccinations were administered
intranasally or subcutaneously. Antibodies (total IgG and IgM as well as subclasses IgG1, IgG2a, IgG2b, and IgG3) were measured
by ELISA. T cell responses (cytotoxic T cells, Th1, Th17, and regulatory T cells) were determined by flow cytometry. When OMV
were used as adjuvant for intranasal immunization, antibody and cellular responses against all three antigens could be induced,
comparable to cholera toxin and MF59C.1. Antigen-specific IgG titres above 1 : 105 could be detected in all groups. This study
provides the rationale for further development of OMV as a vaccination strategy in malaria and other diseases.
1. Introduction
Vaccines are one of the most cost-effective measures in the
field of public health and greatly reduce disease, disability,
death, and inequity worldwide [1, 2]. Their pivotal role has
been demonstrated in infectious disease elimination cam-
paigns (e.g., against smallpox, polio, or measles). However,
due to the diversity of pathogens and their specific require-
ments for immune elimination or prevention, vaccination
strategies cannot be readily translated from one disease to
another, but they rely on a fine definition of protection and
a good understanding of the immunological mechanisms
underlying each vaccination [3].
Most vaccine formulations require adjuvant substances to
boost immune responses, which have to be chosen according
to their ability to induce the desired type of immune response
without causing disproportional toxicity [4]. Another impor-
tant consideration for vaccines is their application route. The
most commonly used parenteral injection depends on the
presence of sterile needles and medical personnel, which are
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major issues in parts of the world where infectious diseases
are most prevalent. Mucosal vaccination strategies have the
potential to overcome these limitations and are thereby in
focus of vaccine research [5]. However, not every potential
application route for mucosal vaccination may be socially
and culturally acceptable. Oral or respiratorymucosal immu-
nization strategies may have the highest acceptance and
may circumvent many of the shortcomings of parenteral
injections. Nonreplicating particles or recombinant proteins
in combination with mucosal adjuvants can evoke mucosal
and systemic immune responses [5]. Immune responses to
vaccines also differ significantly in their ability to induce reac-
tive T cells. Mucosal—especially intranasal (i.n.)—vaccines
have been shown to produce strong T cellular responses [5].
These exquisite properties of mucosal vaccines are in sharp
contrast to their current use, as only few vaccines have been
approved so far for this indication (e.g., against polio, typhoid
fever, or uropathogenic E. coli delivered orally or flu delivered
as nasal spray); all of these consist of attenuated or inactivated
pathogens. A major reason for this discrepancy is the lack of
proper adjuvant substances [6].
Bacterial outer membrane vesicles (OMV) are particles
about 100 nanometres in diameter produced by gram-
negative organisms during growth. OMV encompass gram-
negative outer membrane including transmembrane proteins
as well as periplasmic matter. OMV are inherently potent
immune-stimulators and are able to penetratemucosal mem-
branes as potent danger signal for innate immunity. Together
with heterologous antigens, they can be used as adjuvant
substances to promote immunity to these antigens [7–9]. Sev-
eral studies have investigated the properties of Neisseria spp.
OMV as vaccines as well as adjuvants [10–12]. It is currently
unresolved how OMV would compare with conventional
adjuvants in their capacity to induce immune reactions
against malaria vaccine candidates.
Malaria has a huge impact on public health worldwide,
causing 700,000 [13] to 1.2 million [14] deaths annually.Thus,
there is a need to develop efficient strategies, such as transmis-
sion blocking vaccines. Among several others, two malaria
antigens are deemed suitable for transmission blockade: (i)
the Anopheles alanyl aminopeptidase N (AnAPN1) of the
midgut of Anopheles mosquitoes has been found to play
a critical role in Plasmodium falciparum and Plasmodium
vivax ookinete invasion. Immunization against AnAPN1 was
shown to inhibit Plasmodium replication in mosquitoes and
with this stop transmission [15–18]; (ii) in themalaria parasite
sexual stage, prefertilization gametocyte antigen Pfs48/45
was described to play a critical role in male gamete fertility,
and vaccination can induce potent malaria transmission
blocking antibodies inmice and nonhumanprimates [19–27].
To characterize E. coliOMV as mucosal vaccine adjuvant
in comparison to established adjuvants, mice were vaccinated
with either AnAPN1, Pfs48/45, or ovalbumin (OVA) using
intranasal OMV, intranasal cholera toxin (CT), or subcuta-
neousMF59C.1, respectively. Humoral and cellular responses
were measured after 31 days. This study demonstrates that
OMV elicit robust humoral and cellular immune responses
against the tested antigens. Antibody titres were found to be
comparable between the vaccination groups using the three
different adjuvants. This study provides evidence for further
evaluation of OMV for vaccination against malaria and other
infectious diseases.
2. Materials and Methods
2.1. Construction, Expression, and Purification of Proteins.
The amino acid sequences of AnAPN1 and Pfs48/45 were
used as target antigens for the study. In case ofAnAPN1, a 135-
amino-acid fragment containing the residues 61–194 located
downstream of the N-terminus of mature AnAPN1 was used
as to preserve also the C-terminal transmission blocking
peptide 9, as described previously [15, 17]. In case of Pfs48/45,
the native sequence (accession number AF356146) lacking
the N-terminal signal sequence (amino acid residues 1–27)
and the C-terminal anchor (amino acid residues 428–448)
was used as described before [26]. Amino acid sequences
were reversely translated into coding DNA sequences taking
into account the optimized codon usage for Enterobacteri-
aceae as well as RNA secondary structures and other promi-
nent sequences such as chi sites (DNAStar Inc., Madison,
WI, USA). The resulting DNA sequences were synthetically
generated by GeneArt (Regensburg, Germany). Synthetic
genes were produced including flanking restriction sites for
simplified cloning. For purification, the well-characterized 6-
His tag was fused to the N-terminus of each vaccine protein.
The gene constructs were subcloned into pASK-iba37+ Plas-
mids (IBA-Lifesciences, Goettingen, Germany), using the
restriction sites KpnI/PstI for AnAPN1 and KpnI/HindIII
for Pfs48/45, respectively. Final plasmids were electroporated
into the E. coli strain Top-10 and induced with anhydrotetra-
cycline (AHT). Induction was performed as described by the
manufacturer of the plasmid (IBA-Lifesciences, Goettingen,
Germany). In brief, the specific strain was grown in LB con-
taining ampicillin at a final concentration of 100𝜇g/mL at
37∘Cunder agitation. After anOD
600
of 0.5was reached, AHT
was added to a final concentration of 0.2𝜇g/mL. The induc-
tion was performed for 3 h at 37∘C under agitation. Bacterial
cell pellets were harvested by centrifugation of the induced
culture at 5000×g at 4∘C for 20min and subsequently lysed in
lysis buffer. The proteins AnAPN1 and Pfs48/45, which were
tagged with a 6-His tag at the N-terminal side, were purified
using Ni-nitrilotriacetic acid (Ni-NTA) columns. After sev-
eral wash steps, the proteins were gel filtered to ensure high
purity. Elution was performed under denaturing conditions
with buffer containing 5mM Imidazole and 7M urea.
Cell culture grade, pyrogen-free OVA was purchased
from Sigma-Aldrich (St. Louis, MO, USA); control protein
His-DHFR-m45 stock solution was obtained from previous
productions [28].
2.2. SDS-PAGE and Immuno-Blot Analysis. Discontinuous
one-dimensional sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) was performed with a Protran
II Mini-Vertical unit (Bio-Rad, Munich, Germany). After
electrophoresis, gels were either stained with Coomassie Blue
or transferred to a nitrocellulose membrane (Trans Blot Cell;
Bio-Rad, Munich, Germany). The blot was blocked with 3%
(w/v) bovine serum albumin (BSA) in phosphate buffered
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saline (PBS) supplemented with 0.5% (v/v) Tween and incu-
batedwith dilutedmouse serum. Preimmune or postimmune
sera were used, respectively, followed by goat anti-mouse
immunoglobulin (A, M, or G) peroxidase conjugate (Sigma-
Aldrich, Germany). Blots were developed using enhanced
chemiluminescence (ECL) detection reagents (Amersham
Pharmacia Biotech/GE, Freiburg, Germany). Serum dilu-
tions for IgMwere 1 : 1,000 and for IgG 1 : 20,000. Dilutions of
secondary antibodies used for blot developmentwere 1 : 4,000
for IgG and 1 : 2,000 for IgM.
2.3. Production of Adjuvants and Quantification of OMV.
Cholera toxin (CT) was obtained from Quadratech Diag-
nostics Ltd. (Epsom, UK). MF59C.1 was produced by
Marien-Apotheke München (Munich, Germany). OMVs
were obtained by harvesting from the supernatant of growing
bacterial cultures, as described previously [29]. In brief,
E. coli strain AW OMV01 (Wieser at al., manuscript in
preparation) bacteria were inoculated into prefiltered LB
broth (0.22𝜇m pore size filters; Millipore/Merck, Darmstadt,
Germany) and grown under vigorous agitation and aeration
at 37∘C to an OD
600
up to 2.0. Bacteria were removed from
the culture by centrifugation. The supernatant was sterile
filteredwith 0.45 𝜇mpore size filter (Millipore/Merck, Darm-
stadt, Germany). The OMVs were enriched from filtrates by
ultracentrifugation at 150,000×g at 4∘C for 3 h. The result-
ing translucent pellet was suspended in sterile phosphate
buffered saline (PBS) and stored at 4∘C in the fridge until
use for a maximum of 3 days. Quantification of OMV was
performed as described before [29] using flow cytometry as
well as Bradford protein measurements.
2.4. Vaccination of Animals. Animal experiments were car-
ried out in strict accordancewith the recommendations in the
guidelines of the Federation of European Laboratory Animal
Science Associations. On June 1st, 2012, the accountable
German authority (Government of Upper Bavaria, Munich,
Germany) approved the study protocol. Animals used for
vaccinations were 6- to 8-week-old female pathogen-free
BALB/c mice (Janvier, Saint-Berthevin, France), 14.9 g to
20.3 g of weight. All animals were housed under specific
pathogen-free (SPF) conditions in individually ventilated
positive pressure cabinets (Tecniplast, Hohenpeissenberg,
Germany) with controlled temperature and humidity as well
as strict 12 h day/night cycle. Bedding was autoclaved before
use; sterile water and sniff-extrudated food were offered ad
libitum. Each experiment was repeated at least twice with
5 mice in each group. I.n. vaccination was performed on
days 0, 3, 5, and 21. For vaccination, mice were anesthetized
with isoflurane 4% for a few seconds in the anaesthesiology
chamber of a narcosis device (XGI-8 Gas Anesthesia System;
Xenogen Corporation, Alameda, Ca, USA). Anaesthetized
mice were handled inside the laminar flow hood and the
vaccine was delivered into each nostril using 20 𝜇L Eppen-
dorf GE-Loader tips (Eppendorf, Hamburg, Germany). To
increase stiffness, they were trimmed with sterile scissors to
a total length of about 30mm before use. Each nostril of the
mouse was individually probed and 5 𝜇L of the aqueous vac-
cination solution was administered. The vaccine contained
either (i) 10 𝜇g of the respective vaccine protein (AnAPN1,
Pfs48/45, or OVA) plus CT (Quadratech, Surrey, United
Kingdom) (0.5 𝜇g/10 𝜇L) or (ii) 10 𝜇g of the respective vaccine
protein (AnAPN1, Pfs48/45, or ovalbumin) plus 5 𝜇L OMVs
or (iii) CT (0.5 𝜇g/10 𝜇L) or (iv) 5 𝜇L OMVs. Each (i–iv)
solution was prepared in PBS with adjusted pH of 7.4. All
solutions were freshly prepared and mixed again directly
prior to the application. As an application control PBS was
used (v).
For parenteral application, the subcutaneous (s.c.) vacci-
nation route was chosen inspired by the data of Valensi et al.
[30]. In pilot experiments, we could detect robust immune
responses using subcutaneous immunization rather than
intramuscular while maintaining better tolerability on the
side of the laboratory animal. Doses were administered on
days 0, 7, and 21; a total amount of 20𝜇L of an aqueous
solutionwas inoculated into the scruff of the neck, containing
either (i) 10 𝜇g of the respective vaccine protein (AnAPN1,
Pfs48/45, or OVA) plus 10 𝜇g MF59C.1 or (ii) 10 𝜇g MF59C.1,
each (i, ii) diluted in PBS, or (iii) PBS only as application
control.
All mice were sacrificed on day 31 to obtain mouse sera
and splenocytes to investigate the evoked immune responses.
Throughout the experiments, mice were monitored daily for
abnormalities of behaviour. The weight was determined on a
weekly basis.
2.5. Measurement of the Immune Responses in theMouse. The
antibody response as well as the T cellular response to the
vaccinations was analysed with different methods.
(I) Humoral Immune Response. Serum antibody titres were
determined with ELISA. Titres of total IgG and IgM as well
as the subclasses IgG1, IgG2a, IgG2b, and IgG3 were deter-
mined for each respective antigen and administration route.
For specific serum antibody detection, Nunc Immuno Plates
(Maxisorp F96 flat bottom plate, Sigma-Aldrich, Wies-
baden, Germany) were coated with the respective anti-
gen by incubation of 100 𝜇L of antigen at 20𝜇mol/mL in
carbonate-bicarbonate buffer at 4∘C overnight. The plate
was subsequently washed twice with PBS containing 0.05%
Tween 20 (PBS-T). Nonspecific bindings were saturated with
200𝜇L of blocking buffer (1% bovine serum albumin in
PBS with 0.05% Tween 20) for 1 h at 37∘C. Serum samples
were serially diluted in blocking solution, starting with a
100-fold dilution, and measured in triplicate (some indi-
vidual mouse sera were measured in duplicate because of
small sample volume). Endpoint dilution data from a series
of 16 steps between 1 : 102 and 1 : 106 are presented in Figures
1–3. A 100 𝜇L of diluted serum was incubated for 1 h at
37∘C, followed by four PBS-T washing steps. After addition
of the secondary antibodies, plates were incubated for 1 h
at 37∘C and subsequently washed again four times with
PBS-T. Secondary antibodies conjugated with horseradish
peroxidase (HRP) were used for detection. Read-out was per-
formed with o-phenylenediamine substrate (Sigma-Aldrich,
Wiesbaden, Germany) in 0.1M phosphate/citrate buffer
(pH 5.0). The substrate was incubated for 30min at room
temperature (21 ± 1∘C) under light protected conditions.
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Figure 1: Characterization of the humoral response to ovalbumin
vaccination. Each columndepicts a representative vaccination group
consisting of five mice, respectively. (a) depicts whole IgG and
IgM titres in direct comparison between the three adjuvants. Single
mouse as well as mixed mouse serum data is shown including stan-
dard deviations. For control groups, only three individual mouse
sera were tested additionally to the mixed serum. (b) shows IgG1,
-2a, -2b, and -3 titres of mixed mouse sera in comparison for the
three adjuvant substances including controls. Titres of <102 have not
been determined and thus are not depicted. NS = nonsignificant;∗=
significant difference 𝑝 < 0.05; OMVs = bacterial outer membrane
vesicles; CT = cholera toxin; i.n. = intranasal vaccination; s.c. =
subcutaneous vaccination.
Absorbancewasmeasuredwith a plate reader (Tecan,Grödig,
Austria) at a wavelength of 492 nm according to the instruc-
tions of the manufacturer. Secondary antibodies were chosen
depending on the desired measurement. Whole IgG titres
were determined using goat anti-mouse IgG (Sigma-Aldrich,
Wiesbaden, Germany) diluted 1 : 1,000 in blocking solution;
anti-IgM specific and anti-IgG subclass specific antibodies
(goat anti-mouse IgM, IgG1, IgG2a, IgG2b, and IgG3) were
purchased at Santa Cruz Biotechnology (Santa Cruz, CA,
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Figure 2: Characterization of the humoral response to Pfs48/45
vaccination. Each columndepicts a representative vaccination group
consisting of five mice, respectively. (a) depicts whole IgG and
IgM titres in direct comparison between the three adjuvants. Single
mouse as well as mixed mouse serum data is shown including stan-
dard deviations. For control groups, only three individual mouse
sera were tested additionally to the mixed serum. Immuno-Blot
analysis was performed as a second line of evidence. (b) shows IgG1,
-2a, -2b, and -3 titres of mixed mouse sera in comparison for the
three adjuvant substances including controls. Titres of <102 have not
been determined and thus are not depicted. NS = nonsignificant;∗=
significant difference 𝑝 < 0.05; OMVs = bacterial outer membrane
vesicles; CT = cholera toxin; i.n. = intranasal vaccination; s.c. =
subcutaneous vaccination.
Statistical analysis was performed with the mean optical
density (OD) of each triplicate. A titre measurement was
considered positive when the mean OD value was greater
than the mean OD of the negative controls plus 10 standard
deviations (SD).
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Figure 3: Characterization of the humoral response to AnAPN1
vaccination. Each columndepicts a representative vaccination group
consisting of five mice, respectively. (a) depicts whole IgG and
IgM titres in direct comparison between the three adjuvants. Single
mouse as well as mixed mouse serum data is shown including stan-
dard deviations. For control groups, only three individual mouse
sera were tested additionally to the mixed serum. Immuno-Blot
analysis was performed as a second line of evidence. (b) shows IgG1,
-2a, -2b, and -3 titres of mixed mouse sera in comparison for the
three adjuvant substances including controls. Titres of <102 have not
been determined and thus are not depicted. NS = nonsignificant;∗=
significant difference 𝑝 < 0.05; OMVs = bacterial outer membrane
vesicles; CT = cholera toxin; i.n. = intranasal vaccination; s.c. =
subcutaneous vaccination.
(II) Cellular Immune Response. After completion of the vac-
cination experiment, mice were sacrificed and spleens were
aseptically removed. Spleenswere lysed in lysis buffer (Passive
Lysis Buffer, Promega, Madison, MI, USA) and homogenized
in RPMI 1640 with 10% FCS, 1% Pen/Strep, and 1% L-
Glutamine at a concentration of 7.5 × 106/mL per well in
200𝜇L. Cell count was determined with a Neubauer-chamber.
Single spleen cell suspensions of the vaccinated mice were
pulsed over night with the relevant proteins at the indicated
concentrations (AnAPN1, 0.1mg/mL; Pfs48/45, 0.1mg/mL;
OVA, 0.5mg/mL; or the equivalent volume of PBS). Cells
were restimulated with PMA (50 ng/mL, Sigma-Aldrich,
Wiesbaden, Germany) and Ionomycin (1 𝜇g/mL, Sigma-
Aldrich) for 5 h with the addition of Brefeldin A (1 𝜇g/mL,
Sigma-Aldrich) after 1 h. Cells were surface stained with
anti-CD3-Pe-Cy7 (clone 145-2C11, Biolegend, San Diego, CA,
USA), anti-CD4-PerCP (clone GK1.5, Biolegend), and anti-
CD8-APC-Cy7 (clone 53-6.7, Biolegend). Cells were fixed and
permeabilised using a Foxp3/Transcription Factor Staining
Buffer Set (eBioscience, San Diego, CA, USA). Intracellular
staining was performed with anti-IFN-𝛾-PE (clone XMG1.2,
Biolegend), anti-IL-17-FITC (clone TC11-18H10.1, Biolegend),
and anti-Foxp3-Pacific Blue (clone FJK-16s, eBioscience).
Cells were analysed using a BD FACS Canto II (BD Bio-
sciences, Franklin Lakes, NJ, USA).
2.6. Statistical Analyses. Individual data sets were anal-
ysed using the SigmaStat Software package (Systat Software
GmbH, Erkrath, Germany). ELISA data were compared with
theMann-Whitney rank sum test, as data was not always nor-
mally distributed; flow cytometric data was analysed using
Student’s 𝑡-test. 𝑝 values of <0.05 were considered statistically
significant and marked with ∗.
3. Results
3.1. Preparation of AnAPN1, Pfs48/45, and OMV. The G/C
contents of AnAPN1 and Pfs48/45 sequence after codon har-
monization were 49.19% and 41.63%, respectively (see Text S1
in the Supplementary Material available online at http://dx
.doi.org/10.1155/2016/3576028). Protein properties can be found
in more detail in the Supplementary Material (Text S2). Codon
usage was significantly improved for enterobacterial prefer-
ence in the synthetic genes. Expression and purification were
performed as described in more detail in Section 2 (see also
Text S3). Induction in transgenic E. coli yielded sufficient pro-
tein amounts for vaccination experiments; the concentration
of vaccine protein in the final elution sample was 4.5mg/mL
for AnAPN1 and 3.2mg/mL for Pfs48/45, respectively. The
lipopolysaccharide content of the protein preparations was
determined and found to be equal to an LPS load for each
administration (10 𝜇g) of 0.02 ng in the case of AnAPN1 and
0.03 ng for Pfs48/45, respectively. OMVs were produced as
described above and before [29]. Emulsified OMVs were
diluted to a concentration of 5 × 106/𝜇L for the use as adjuvant.
3.2. Immunization. In each vaccination group, a total of five
mice were vaccinated. Individual experiments were repeated
twice independently. Vaccinations were well tolerated with-
out any noticeable local or systemic adverse events. Labora-
tory animals were observed daily and with special scrutiny
the hours following the administration of the vaccines. Stan-
dardized score sheets were used to document behaviour and
weight. No significant difference in weight gain or behaviour
could be observed between groups; no signs of acute toxicity
could be observed.
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3.3. ELISA. In the OVA groups, total IgG titres reach up to
1 : 106, equally distributed between the i.n. vaccination routes
(Figure 1). The titres of s.c. vaccination with MF59C.1 were
significantly lower than with both i.n. routes. For all three
vaccines, IgG1 is the main IgG subclass evoked, again with
the intranasal routes being superior to the s.c. administration.
IgG3 subclass titres were found at similar levels compared to
IgG1 for all vaccine routes. IgM titres are only roughly one
order ofmagnitude below IgG titres even after onemonth. All
titres increased significantly during the course of vaccination.
Detectable IgM persisted throughout the experiment in the
groups of all three adjuvants. Although the overall IgG titres
in the MF59C.1 group were lower, the IgM titres were not
significantly different in all three groups.
In the groups vaccinated with Pfs48/45, total IgG titres
were in the range of >105-106 (Figure 2).
In Western Blot analysis, a strong IgG reaction can be
detected. Interestingly, a higher molecular mass band can be
seen in the OMV i.n. Pfs48/45 group and to a lesser extent in
the other Pfs48/45 vaccinated groups. It could not be detected
in the mock-immunized groups. Mice vaccinated with i.n.
OMV and to a lesser extent those vaccinated with MF59C.1
had persistent IgM and low IgG3 titres. However, substantial
IgM titres were observed in the ELISA measurements also
of the mock-immunized groups. Thereby, the Western Blot
analysis could only detect a specific reaction in the Pfs48/45
groups immunized with OMV as well as MF59C.1, which
also demonstrated a significantly higher titre in the vacci-
nated group as compared to the mock-immunized control
(Figure 2). In contrast, mice vaccinated with i.n. CT had no
persistent IgM but had higher IgG3, with titres for IgG3 being
higher than those for IgG2b. Most of the IgG response was of
the IgG1 subclass in all vaccination groups. OMV vaccinated
mice had, however, lower IgG1 titres compared to the other
groups. Overall, titres achieved with the s.c. vaccination were
significantly higher than in the other two groups.
Mice vaccinated with AnAPN1 developed high titres of
up to 106 (Figure 3). Mucosal vaccination showed a trend
towards higher titres compared to the parenteral vaccination.
For all groups, no IgM persistence above the titres of the
mock-immunized groups could be observed and IgG3 titres
were lower than IgG2a and -b titres. MF59C.1 vaccination
induced the lowest IgG2a titres.
When controlling all titres against a decoy protein (DHFR
of the mouse) with identical N-terminal signal sequences
and His tag as used in AnAPN1 and Pfs48/45, respectively,
no deviation from background could be detected in any
group, excluding unspecific binding to the purification tag
sequences.
3.4. T Cell Response. OVA was used as model antigen, in
order to analyse the ability of the used adjuvants (CT,
MF59C.1, and OMV) to induce an antigen-specific cellular
response. All three adjuvants were able to induce OVA-
specific cytotoxic T cells (Figure 4(a)). CT was better than
MF59C.1 and showed a trend towards stronger induction
of cytotoxic T cells than OMV (Figure 4(a)). CT was the
only adjuvant able to induce a Th1 response towards OVA
(Figure 4(b)), while MF59C.1 and OMV did not. None of the
adjuvants induced a significant number of OVA-specificTh17
or regulatory T cells (Figures 4(c) and 4(d)).
In contrast, when comparing the ability of the said adju-
vants to induce AnAPN1-specific cellular responses, only
OMV was able to induce a cytotoxic T cell response towards
AnAPN1, but all induced aTh1 response towards the antigen
(Figures 5(a) and 5(b)). Again, no induction of antigen-spe-
cific Th17 or regulatory T cells (Figures 5(c) and 5(d)) could
be observed.
When assessing the responses induced by Pfs48/45 vac-
cination, we found a decrease in cell number for all the con-
ditions where cells have been restimulated with Pfs48/45
(Figure S4). All cell populations including cytotoxic T cells,
Th1 cells, Th17 cells, and regulatory T cells decreased upon
restimulation with Pfs48/45 (Figure S4).
4. Discussion
In the present study, humoral and cellular immune responses
evoked by different vaccinationmethods usingmalaria trans-
mission blocking antigens and ovalbumin in mice have been
characterized and compared [15–27]. This study is the first
to compare humoral and cellular immune responses for i.n.
OMV adjuvating malaria transmission blocking antigens.
Purified antigens from transgenic bacterial cultures (or pur-
chased, in the case of OVA) were used and mixed with
the respective adjuvant. This strategy does not make use of
the full capacity of OMV for vaccination, as the antigens
can be expressed directly inside the OMV [31]. To allow
direct comparison of the vaccination routes, the same antigen
batch was used with the different adjuvants. This approach
considerably reduces possible artefacts due to folding abnor-
malities or contaminations of the used antigen preparation.
However, this cannot control for antigen losses, which are to
be expected due to uptake on themucosal surface or sneezing
out of the vaccination solution by the animals. To allow for
a better evaluation of our results and comparison with liter-
ature, three previously studied antigens have been used. In
this study, an adjuvant licensed for humanuse (MF59C.1) [32]
and two mucosal adjuvants were used. While cholera toxin
cannot be used in humans due to toxicity, it is considered
highly potent and can be used as the reference substance in
mice [33].
Previously, the use of modified OMV for i.n. vaccination
has been reported and also been used as intranasal adjuvant
[12], but concerns about their endotoxin (LPS) content is
seen as problematic especially for parenteral application. To
circumvent this issue, injectable formulations use extracted
OMV without large amounts of LPS [34]. Mucosal surfaces
may be less sensitive to LPS, since these are generally
colonized by bacteria and thus potentially more amenable to
safe OMV usage [35].
Humoral immune responses are key for the success of
classic vaccine antigens [3]. For the malaria transmission
blocking antigens AnAPN1 and Pfs48/45, antibodies are piv-
otal for transmission blockade in the midgut of the mos-
quitoes and IgGs seem to be of primary importance [15–
27]. Although, for malaria transmission blocking vaccines,
the long-term antibody response is important and has not
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Figure 4: Characterization of the cellular response to ovalbumin vaccination. Each dot or triangle represents an individual mouse. Each PBS
vaccination consisted of four mice and each ovalbumin vaccination group of five mice. Comparisons between groups were performed by
Student’s 𝑡-test. (a) Percentage of IFN-g secreting CD3 and CD8 double positive cells. (b) Percentage of IFN-g secreting CD3 and CD4 double
positive cells. (c) Percentage of IL-17 secreting CD3 and CD4 double positive cells. (d) Percentage of Foxp3 positive CD3 and CD4 double
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Figure 5: Characterization of the cellular response to AnAPN1 vaccination. Each dot or triangle represents an individual mouse. Each PBS
vaccination consisted of four mice and each AnAPN1 vaccination group of five mice. Comparisons between groups were performed by
Student’s 𝑡-test. (a) Percentage of IFN-g secreting CD3 and CD8 double positive cells. (b) Percentage of IFN-g secreting CD3 and CD4 double
positive cells. (c) Percentage of IL-17 secreting CD3 and CD4 double positive cells. (d) Percentage of Foxp3 positive CD3 and CD4 double
positive cells. NS = nonsignificant; ∗ = significant difference 𝑝 < 0.05; OMVs = bacterial outer membrane vesicles; CT = cholera toxin; ND =
not determined.
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been studied here, antibodies evoked at the peak of the
immune response are of interest, offer valuable first insights
into immunogenicity, and help with the design of studies
covering the more antigen-specific application areas.
In the OVA vaccination groups, the total IgG titres of
the i.n. groups were significantly higher than in the MF59C.1
adjuvated, s.c. administered animal batch (Figure 1). Injected
OVA was previously found to be very immunogenic [36].
These high titres after i.n. vaccination are surprising, as OVA
administered intranasally with liposomes was previously
found to be less efficient than in combination with CT [37,
38]. High IgG3 titres, which were significantly lower than
IgG1 in all groups, and persistent IgM were observed as
well (Figure 1). This is noteworthy as two of the protocols
involved the i.n. application of the antigen/adjuvants mixture
rather than the injection. Therefore, it is possible that the
properties of OVA as an antigen influenced the antibody
subclass distribution rather than the application route or
adjuvant substance. Other studies using different adjuvant
substances reported IgG2a titres to be higher than IgG3 when
injected with CpG, Bp, and CFA, respectively [36]. In these
studies, however, i.n. routes have not been used at all and a
clear influence of the adjuvant substance can be seen. OVA
groups show a strong Th2 dependent response with IgG1 as
the most dominant subclass (Figure 1). Nevertheless, IgG2a
titres are only one order of magnitude lower in titre levels
than IgG1 and are still in the range of 1 : 105 (Figure 1). This
argues for a strongTh1 answer as well [39]. Besides these two,
the T cell independent IgG3 reaches almost the same level as
IgG1, which is noteworthy.
Titres in the Pfs48/45 groups were on average similar
to the OVA titres, however, with a tendency to be lower
especially in the i.n. groups (Figure 2). The s.c. group
vaccinated with MF59C.1 actually showed the highest titre
measured in the experimental series described here.The titres
for total IgG were not different between the i.n. groups,
however, significantly higher in the s.c. group (Figure 2).
In Western Blot analysis, a higher molecular weight band
can be appreciated in the OMV i.n. Pfs48/45 vaccinated
group and to much less extent also in the MF59C.1 and
CT groups (see Figure 2(a)). This band is most likely a
very slight reaction against traces of larger molecular weight
protein found within the purified Pfs48/45 stock (see also
silver stain in Supplementary Material (S3)), which is most
prominently seen in the OMV vaccinated group. However,
it is not present in the controls; thus a significant unspecific
reaction can be excluded. Interestingly, IgM titres persisted
significantly above the controls in the OMV i.n. group and
the MF59C.1 group but not in the CT group (Figure 2). The
OMV adjuvated i.n. administration also has low IgG3 levels
as well as relatively low IgG2a levels (Figure 2). Therefore,
the antibody response in this route seems to be mainly Th2
based. In contrast, the MF59C.1 groups showed significantly
higher IgG3 titres (Figure 2). Thus, besides the strong Th2
mediated IgG1 response T cell independent IgG3 seems to
be of greater importance than with the OMV adjuvated i.n.
group. The CT i.n. group shows an intermediate phenotype
as compared to the two other groups. Interestingly, the OMV
adjuvant was able to stimulate a strong IgG3 response in
the OVA-experiment and also strong Th1 mediated IgG2a
titres in the OVA as well as AnAPN1 group (see Figures 1
and 3, resp.). IgG3 has been described before to be the second
most important antibody subclass evoked after vaccination
with Neisseria OMV [40]. The lack of IgG3 and IgG2a has to
be attributed not to the properties of the adjuvant itself but
rather to the combination of the adjuvant with the antigen,
or possible penetration, or uptake problems of the antigen
Pfs48/45 when administered in the i.n. application route.The
overall size of the Pfs48/45 protein construct was relatively
large with 49.4 kDa and charge is comparatively strong (−10.8
at pH 7), whereas AnAPN1 is much smaller and with less
charge (18.3 kDa and −1.2 at pH 7), and OVA, although
of roughly the same size (45 kDa), is favourable regarding
solubility and charge (Text S2). Still, the humoral immune
response was strong in all groups, never reaching titres below
1 : 105 (Figures 1–3).
Overall the OVA and Pfs45/48 vaccinations had a ten-
dency of reaching higher average titre levels over all three
vaccination routes (both 1.1 × 106) as compared to AnAPN1
(6.1 × 105) (Figure 3), arguing for all three application routes
to be a relatively robust system, although the difference
in size and physical properties are striking (Text S2). The
AnAPN1 vaccination groups do not show significant differ-
ences between the application routes regarding the total IgG
titres (Figure 3). There seems to be a trend towards higher
titres on the side of the i.n. groups as compared to the s.c.
group, but this was not significant. All groups lean towards an
IgG1 based response, which ismost dominant in theMF59C.1
group (Figure 3). Other than with OVA, the different sub-
class distribution patterns argue for a more Th1/2 balanced
response with the OMV group and a mostly Th2 biased
answer in the MF59C.1 group. All three groups show only
relatively low IgG3 levels; thus T cell independent IgG3might
not be easily generated with AnAPN1, which is in accordance
with a previous study using incomplete Freund’s adjuvant
and Alhydrogel in BALB/c and Swiss Webster mice [17]. This
may be due to properties of the antigen itself rather than the
adjuvant substance, as high IgG3 levels could be detectedwith
all three adjuvants when applied together with OVA. Subclass
antibody data published previously for Pfs48/45 vaccination
trials also showed dominating IgG1 responses with highly
variable contributions of IgG2a, IgG2b, and IgG3 depending
on adjuvants (Montanide ISA-51, Alum, CFA) and/or animal
models (olive baboons, BALB/c mice) used [26].
The induction of T cell responses through vaccination
does not only rely on the adjuvant and the administration
route used, but also rely on the target antigen and its
amenability to MHC-I or II presentation [41, 42]. All adju-
vants of the present studywere able to support cytotoxic T cell
responses towards OVA (Figure 4(a)). However, only OMVs
could induce such T cells against AnAPN1 (Figure 5(a)).
Therefore, the difference observed with this antigen cannot
be explained by the general capacity of the adjuvant to induce
CD8 T cell responses, but rather by the nature of the antigen
which may not be readily accessible to the MHC presenting
machinery and requires adequatematuration and stimulation
of antigen-presenting cells for proper immune induction
as was described for other antigens [43]. A lack of proper
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presentation of AnAPN1 during restimulation in vitro can
be ruled out, since reactive T cells could be detected in the
case of OMV. In this setting, OMVs seem to mediate best
antigen presentation of AnAPN1 in vivo leading to measur-
able immune responses compared to the other adjuvants.
It is also important to note that no induction of antigen-
specific regulatory T cells could be found which would have
hampered the function of effector T cells and thus hijacked
any therapeutic benefit [44]. CD8 positive T cells may be
important for malaria protection but are not needed for
malaria transmission blocking activity [15–27, 45]. However,
levels can be used to better characterize the immune response
supported by the individual route. The data, however, cannot
preclude an advantage over other types of vaccination based
on the induction of CD8 T cell responses [46].
While IgG1 was the most prominent antibody subtype
detected for all antigens and adjuvants, only Th1 but not Th2
cellular responses could be detected upon restimulation.Th2
cells may be below the limit of detection. The analysis of
antibody subtypes at the time point of sampling also revealed
persistence of IgM, potentially indicating an incomplete class
switch towards IgG at that time point. The analysis is, how-
ever, somewhat hampered by the relatively high background
titres observed in the mock-immunized adjuvant control
groups whichmay demonstrate increased unspecific reaction
in the directly coated ELISA. The increased titres in the
mock controls were observed mainly with the Pfs48/45 and
AnAPN1 groups and to much less extent in the OVA group
(Figures 1, 2, and 3). The Western Blot controls performed
in parallel only displayed a specific but weak reaction in the
Pfs48/45 groups immunized in conjunction with OMV or
MF59C.1 (Figure 2). Such delayed isotype switch has been
described upon infection [47]. Cellular responses against
Pfs48/45 could not be detected due to toxicity of the protein
whenused in the restimulation protocol (Figure S4). Pfs48/45
cytotoxicity in vivo, however, seems not to be relevant.
The detected antibody response requires CD4 T helper cell
support and thus proves the existence and function of these
T cells in vaccinated mice [48]. Furthermore, no significant
side effects or reduced weight gain was observed in the
experimental groups confronted with Pfs48/45 compared to
the other antigens and the application controls arguing for
negligible toxic effects on the mouse in vivo.
5. Conclusions
The results of this study argue that, based on the antigen-
adjuvant cocktail chosen, humoral and cellular immune
responses may be shaped differently. They also suggest that
i.n. vaccination with OMV may be a potent strategy to
enhance intranasal heterologous vaccine antigens. OMV-
evoked antibody titres and T cell responses were about as
strong as after i.n. immunization with CT. This aspect is of
special importance as OMV application to the nasal mucosa
may eventually be considered an easy and safe vaccination
route as compared to CT, which is not used in humans
due to toxicity. Importantly, i.n. vaccination led to robust
and reproducible immune responses, indicating that antigen
application and uptake do not limit the approach, even using
antigens of large size andwith strong charge such as Pfs48/45.
Parenteral applications such as the MF59C.1 adjuvated group
used here provide an almost complete antigen bioavailabil-
ity; however, the immune responses were not found to be
significantly better than with mucosal routes with uncertain
bioavailability. The results provide the rationale for further
improvement and engineering of OMV to facilitate their
adherence to mucosal surfaces and boost of the immune
response. Further studies are also aiming at directly coupling
(malaria) antigens to OMV and at generating transgenic
bacterial strains where supernatant can be used directly as a
vaccine for use in resource limited settings.
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